The present invention relates generally to the field of medical devices for providing fluid to a patient. More specifically, the present invention relates to infusion pumps configured to prevent or compensate for degradation of infusion tubes operationally connected to the pump.
Infusion pumps are configured to administer fluid to a patient via a conduit such as an infusion tube or a cassette at high accuracy and often for a prolonged period of time. Infusion tubes are accommodated in the infusion pump in such manner that a plunger can squeeze the surface of the infusion tube, thereby causing delivery of the infusion fluid.
Infusion pumps administer fluids in ways that would be impractical and expensive/unreliable if performed manually by nursing staff. For example, an infusion pump assembly may repeatedly administer small quantities of an infusible fluid (e.g., 0.1 mL per hour). However, common disposable infusion tubes are prone to deform or rupture when being continuously compressed, consequently affecting the precision of the delivery.
The hereindisclosed infusion pump advantageously includes a controller configured to control the position of a plunger in such manner that an infusion tube connected to the infusion pump remains partially squeezed dozing essentially the entire operation of the pump.
That is, in its upper position (also referred to herein as an upper squeezing position) the plunger mildly squeezes the infusion tube, such that opposite sides of an inner surface of the infusion tube do not contact each other. This is as opposed to common infusion pumps, which in their upper position (also referred to herein as an uppermost position) do not squeeze the infusion tube; in fact, the plunger is typically elevated to a position in which it does not touch the infusion tube's outer surface.
As used herein, the term “mildly squeezing” refers to the plunger pressing upon the infusion tube sufficiently to cause a change in the shape of the infusion tube's inner lumen, as compared to a hilly relaxed tube. According to some embodiments, at its upper squeezing position, when mildly squeezed, the infusion tube is more than 0% and less than 10% squeezed, as compared to a hilly squeezed infusion tube. According to some embodiments, at its upper squeezing position, when mildly squeezed, the infusion tube is more than 5% and less than 10% squeezed, as compared to a hilly squeezed infusion tube.
In the plunger's lower position (also referred to herein as a lower squeezing position), the squeezing of the infusion tube is increased, yet still the opposite sides of the inner surface of the infusion tube do not contact each other. Again, this is different than common infusion pumps, which typically are configured to squeeze the infusion tube to a maximum (also referred to herein as a lowermost position), i.e. such that the opposite sides of the inner surface of the infusion tube become basically aligned. According to some embodiments, in its lower squeezing position, the infusion tube is less than 100% squeezed and more than 80% squeezed, as compared to a fully squeezed infusion tube. According to some embodiments, in its lower squeezing position, the infusion tube is less than 95% squeezed and more than 80% squeezed, as compared to a fully squeezed infusion tube.
Advantageously switching between intermediate rather than extreme positions ensures accurate delivery even during prolonged delivery.
Complete squeezing of the infusion tube causes bottoming out and high stress to the tubing walls, which in turn leads to continuous degradation and impaired accuracy over time. This is particularly a problem when utilizing DEHP-free PVC, since PVC is an overdamped spring that does not truly hollow the plunger, as opposed to, for example, silicon tubes. Utilizing a less severe lower position advantageously prevents such degradation.
In addition, due to the plunger executing a mild squeeze even in the upper position (deeper upper position of the plunger), the tube follows the plunger to the upper position and the springiness of the tubing is thus maintained throughout the pumping cycle. As a result, the need for incorporating complicated algorithms in an attempt to compensate for changes in flow rate over time is obviated. In fact, the flow rate stability of the hereindisclosed infusion pump is far superior to that of infusion pumps utilizing flow rate compensation algorithms as further demonstrated hereinbelow.
According to some embodiments, the infusion pump, disclosed herein, is further configured to determine a wait period during which the plunger “waits” in its (deep) upper position, prior to the opening of the infusion pump's downstream valve. This allows the infusion tube to fully engage the plunger prior to the opening of the downstream valve, and thus increases accuracy, as the volume of the tube is constant. In addition, an ascending of the infusion tube whilst the downstream valve is open, causing liquids to be extracted from the patient, is beneficially prevented.
According to some embodiments, during the intake phase (suction of liquid from an IV bag or syringe), the plunger can be raised to a position above the upper position and then descended back to the upper position, mildly squeezing the infusion tube. This does not only allow more room for relaxation of the infusion tube, but also enables pumping a small bolus into the syringe, thus reducing the vacuum that is created during the intake.
Advantageously the controller may be configured to calibrate and/or optimize the upper and lower squeezing positions of the plunger, thus facilitating operation with infusion tubes of different dimensions and consistencies.
According to some embodiments, there is provided an infusion pump comprising a plunger; a proximal valve located proximally to said plunger; a distal valve located distally to said plunger; and a controller configured to control infusion fluid delivery to the subject and infusion fluid intake from a reservoir (also referred to as an infusion source). The controlling of the intake of fluid comprises: closing of said distal valve, opening of said proximal valve, moving of said plunger to an upper squeezing position, in which upper squeezing position of said plunger is configured to partially squeeze an infusion tube, while facilitating intake of fluid; and determining a “wait” period, following the intake, during which wait period said plunger remains at said upper squeezing position, thereby ensuring full recovery of the tube to engagement of the infusion tube with the plunger. The controlling delivery comprises: closing of said proximal valve and opening of said distal valve, while said plunger is at the upper squeezing position, descending of said plunger from the upper squeezing position to a lower squeezing position, wherein at both the upper squeezing position and the lower squeezing position, said plunger is configured to squeeze a section of an infusion tube, such that opposite sides of an inner surface of said section do not contact one another, thereby facilitating delivery of an essentially constant volume of infusion fluid to the subject regardless of a potential degradation of the infusion tube.
According to some embodiments, the plunger is configured to contact an outer surface of the infusion tube from the end of intake to end of delivery operation thereof.
According to some embodiments, at the lower squeezing position, the plunger is configured to squeeze the section of the infusion tube to form a first inner tube cross section and wherein, at the upper squeezing position, the plunger is configured to squeeze the section of the infusion tube to form a second inner tube cross section, wherein the second inner tube cross section is larger than the first inner tube cross section and smaller than a cross section of the infusion tube, when not-squeezed.
According to some embodiments, the infusion pump further comprises a motor in communication with the controller, the motor configured to operate the plunger. According to some embodiments, the motor is further configured to operate the proximal valve, the distal valve or both. Additionally or alternatively, the infusion pump further comprises a second motor configured to operate the proximal valve, the distal valve or both.
According to some embodiments, the infusion tube is a DEHP-free PVC infusion tube.
According to some embodiments, the controller is configured to calibrate the upper squeezing position and the lower squeezing position of the plunger according to dimensions of the infusion tube.
According to some embodiments, controlling the intake of infusion fluid further comprises initially positioning of the plunger to a position above the upper squeezing position followed by a descending of the plunger to the upper squeezing position, while the proximal valve is open, thereby allowing residual fluid to backflow towards the reservoir.
According to some embodiments, the wait period has a maximum duration based on and/or defined by the flow continuity and flow rate.
According to some embodiments, there is provided an infusion pump comprising: a plunger; a proximal valve located proximally to the plunger; a distal valve located distally to the plunger; and a controller configured to control an infusion fluid delivery to the subject and an infusion fluid intake from a reservoir. Controlling the intake of fluid comprises: closing of said distal valve, opening of said proximal valve, moving of the plunger from the lower position to the upper position and above an upper squeezing position; and descending of the plunger to the upper squeezing position, in which upper squeezing position the plunger is configured to partially squeeze an infusion tube, while allowing intake of infusion fluid. Controlling the intake of infusion fluid further comprises determining a “wait” period, following the intake, during which wait period the plunger remains at the upper squeezing position or above it, thereby ensuring engagement of the infusion tube with the plunger.
According to some embodiments, controlling the delivery of the infusion fluid comprises: closing of the proximal valve and opening of the distal valve, while the plunger is at the upper squeezing position, descending of the plunger from the upper squeezing position to a lower squeezing position, wherein at both the upper squeezing position and the lower squeezing position, the plunger is configured to squeeze a section of an infusion tube, such that opposite sides of an inner surface of the section do not contact one another, thereby facilitating delivery of an essentially constant volume of infusion fluid to the subject regardless of a potential degradation of the infusion tube.
According to some embodiments, the plunger is configured to contact an outer surface of the infusion tube section during the entire delivery thereof.
According to some embodiments, the infusion pump further comprises a motor in communication with the controller, the motor configured to operate said plunger. According to some embodiments, the motor is further configured to operate the proximal valve, the distal valve or both. Additionally or alternatively, the infusion pump further comprises a second motor configured to operate the proximal valve, the distal valve or both.
According to some embodiments, the infusion tube is a DEHP-free PVC infusion tube.
Certain embodiments of the present disclosure may include some, all, or none of the above advantages. One or more technical advantages may be readily apparent to those skilled in the art from the figures, descriptions and claims included herein. Moreover, while specific advantages have been enumerated above, various embodiments may include all, some or none of the enumerated advantages.
In addition to the exemplary aspects and embodiments described above, further aspects and embodiments will become apparent by reference to the figures and by study of the following detailed descriptions.
Examples illustrative of embodiments are described below with reference to figures attached hereto. In the figures, identical structures, elements or parts that appear in more than one figure are generally labeled with a same numeral in all the figures in which they appear. Alternatively, elements or parts that appear in more than one figure may be labeled with different numerals in the different figures in which they appear. Dimensions of components and features shown in the figures are generally chosen for convenience and clarity of presentation and are not necessarily shown in scale. The figures are listed below.
In the following description, various aspects of the disclosure will be described. For the purpose of explanation, specific configurations and details are set forth in order to provide a thorough understanding of the different aspects of the disclosure. However, it will also be apparent to one skilled in the art that the disclosure may be practiced without specific details being presented herein. Furthermore, well-known features may be omitted or simplified in order not to obscure the disclosure.
According to some embodiments, there is provided an infusion pump including a plunger; a proximal valve located proximally to the plunger; a distal valve located distally to the plunger; and a controller configured to control an infusion fluid delivery to the subject, wherein controlling delivery comprises triggering closing of the proximal valve, while the plunger is at an upper squeezing position, and triggering descending of the plunger from the upper squeezing position to a lower squeezing position, wherein at both the upper squeezing position and the lower squeezing position, said plunger is configured to squeeze a section of an infusion tube, such that opposite sides of an inner surface of said section do not contact one another, thereby facilitating delivery of an essentially constant volume of infusion fluid to the subject regardless of a potential degradation of the infusion tube.
As used herein, the term “upper squeezing position” refers to a position of a plunger at which an infusion tube is mildly squeezed (i.e. higher than a position at which the tube is not squeezed), without having the opposite sides of an inner surface of the squeezed section contacting one another. According to some embodiments, the delivery phase of the infusion pump is initiated at “upper squeezing position”.
As used herein, the term “lower squeezing position” refers to a position of the plunger at which an infusion tube is squeezed to a larger extent as compared to the upper squeezing position, yet still without having the opposite sides of an inner surface of the squeezed section contacting one another. According to some embodiments, the delivery phase of the infusion pump is initiated at “upper squeezing position”.
As used herein, the term “degradation” may refer to the tube losing its springiness, becoming deformed, bottoming out, or otherwise changing its shape or consistency in a manner affecting the drug delivery accuracy. According to some embodiments, the infusion tube may be a DEHP-free PVC infusion tube, a DEHP containing infusion tube, a polyethylene (PE) tube, a silicone tube, or the like. Each possibility is a separate embodiment.
As used herein, the term “infusion fluid” may refer to any fluid delivered to the patient such as, but not limited to, insulin, nutrients, saline solution, antibiotics, analgesics, anesthetics, hormones, vasoactive drugs, and chelation drugs, and any other therapeutic fluids or combination of fluids.
According to some embodiments, the plunger is configured to contact an outer surface of the infusion tube section during essentially the entire operation of the infusion pump. According to some embodiments, the plunger is configured to contact an outer surface of the infusion tube section during essentially the entire phase of delivery of the infusion fluid to the subject. According to some embodiments, the plunger is configured to some extent squeeze the infusion tube section, without having the opposite sides of an inner surface of the squeezed section contacting one another, during essentially the entire operation of the infusion pump. According to some embodiments, the plunger is configured to some extent squeeze the infusion tube section, without having the opposite sides of an inner surface of the squeezed section contacting one another, during essentially the entire phase of delivery of the infusion fluid to the subject. According to some embodiments, the plunger does not facilitate full relaxation of the infusion tube at any point of operation. According to some embodiments, the plunger does not fully squeeze/press the infusion tube at any point of operation.
As used herein, the term “entire” may refer to at least, at least 95% or at least 98% of the operation of the infusion pump/of the delivery phase. It is thus understood that briefly elevating the plunger during operation may be within the scope of this disclosure.
As used herein, the term “to some extent” with referral to the squeezing of the infusion tube refers to a squeezing of the infusion tube rendering the cross section of the squeezed section's lumen smaller than that of the infusion tube when non-squeezed, without having the opposite sides of an inner surface of the squeezed section contacting one another.
According to some embodiments, at the upper squeezing position, the plunger is configured to squeeze the section of the infusion tube to form a first inner tube cross section and wherein at the lower squeezing position, the plunger is configured to squeeze the section of the infusion tube to form a second inner tube cross section, wherein the second inner tube cross section is smaller than the first inner tube cross section and larger than a cross section of the infusion tube when non-squeezed.
According to some embodiments, the inner tube cross section of the infusion tube when the plunger is in its upper position is 50%-90% the size of the inner tube cross section of the infusion tube when non-squeezed. Each possibility is a separate embodiment.
According to some embodiments, the inner tube cross section of the infusion tube when the plunger is in its lower position is between 50%-10%, larger than the size of the inner tube cross section. Each possibility is a separate embodiment.
Any combination of upper and lower squeezed positions is a specific embodiment.
According to some embodiments, for a typical tube of 3 mm inner diameter and a wall thickness of 0.5 mm, a typical upper squeezing position, of the plunger is positioned about 0.8 mm to 1.8 mm, lower than the diameter of a non-squeezed tube. Each possibility is a separate embodiment.
According to some embodiments, for the same tube defined above, the lower squeezing position of the plunger is positioned about 2.0 mm-2.8 mm, below the non-squeezed tube. Each possibility is a separate embodiment.
According to some embodiments, the infusion pump is configured to maintain an essentially constant flow rate during the entire delivery of an infusion fluid. As used herein, the term “essentially constant” refers to a flow rate changing by less than 2% during the entire delivery. As a non-limiting example, the infusion pump is configured to maintain a delivery of an infusion fluid at a flow rate of 1 mL/hour±0.01 mL for at least 20, at least 36 or at least 96 hours.
According to some embodiments, the controller is further configured to control the intake of an infusion fluid from a reservoir, such as, but not limited to, an IV-bag or a syringe. According to some embodiments, controlling the intake of the infusion fluid comprises triggering opening of the proximal valve, closing of the distal valve and elevating the plunger to the upper squeezing position. According to some embodiments, during the intake phase, the plunger may initially be elevated to a position above the upper squeezing position for a brief moment (e.g. 1 sec or less) and then lowered back to the upper squeezing position. This may advantageously allow more room for the infusion tube to assume a relaxed configuration. In addition, when using a syringe as the reservoir, the initial elevation of the plunger to a position above the upper squeezing position prior to assuming the upper squeezing position may pump a small bolus into the syringe, thus reducing the residual vacuum left in the syringe at the end of the intake.
According to some embodiments, the pump further includes a motor in communication with the controller, the motor configured to operate the plunger. According to some embodiments, the motor may further be configured to operate the proximal valve, the distal valve or both. Alternatively, the pump may include one or two additional motors configured to operate the proximal valve, the distal valve or both. According to some embodiments, the controller may control the operation of the motor, thereby determining the exact position of the plunger. This may advantageously allow calibrating the upper and lower squeezing positions vis-à-vis the floor against which the infusion tube is squeezed according to dimensions and/or consistency of the infusion tube.
According to some embodiments, the controller may further be configured to determine a “wait” period, during which wait period the plunger remains at the upper squeezing position, thereby ensuring full engagement of the infusion tube with the plunger, prior to the opening of the infusion pump's downstream valve. This advantageously increases the accuracy of infusion fluid delivery in that the volume delivered remains constant even if the infusion tube has undergone degradation. Furthermore, due to the infusion tube fully engaging the plunger, a persistent ascending of the infusion tube after opening of the downstream valve is essentially prevented. Extraction of liquids from the patient is prevented. The length of the wait depends on the flow continuity requirements and the flow rate. For low flow rates (1-10 mL/hr) and flow continuity of bolus every 20 sec, the wait can last up to 18 sec. For high flow rates, the wait time is shorter (e.g. about 10 sec) and for very high flow rates (999 mL/hr) it may last less than 1 second. The long wait is particularly advantageous for low flow rates where the tube squeeze duty cycle is very long.
According to some embodiments, the wait period may be at least two seconds, or at least 5 seconds. According to some embodiments, the duration of the wait is dependent on the flow rate of the infusion fluid and/or the length of the plunger.
According to some embodiments, there is provided a method of operation of an infusion pump, the method comprising;
According to some embodiments, the infusion tube is at no point of operation fully squeezed/pressed by the plunger.
According to some embodiments, the method may further include briefly elevating the plunger to a position above the upper squeezing position, (while the proximal valve is open, and the distal valve closed) prior to the positioning of the plunger at the upper squeezing position, thereby allowing a small bolus of infusion fluid to flow into the syringe, thus reducing the vacuum created therein during the intake, as well as allowing more room for the infusion tube to assume a relaxed configuration.
According to some embodiments, the method may further include determining a “wait” period configured to ensure full engagement of the infusion tube with the plunger, wherein during the wait period the plunger remains at the upper squeezing position, prior to the opening of the infusion pump's downstream valve.
Reference is now made to
As evident from
Reference is now made to
Advantageously and as evident from
Reference is now made to
According to some embodiments, the controller may further be configured to define a “wait” period configured to ensure full engagement of infusion tube 350 with the plunger 310, wherein, during the wait period, plunger 310 remains at the upper squeezing position, while distal valve 325 is open. As a non-limiting example, if the maximum no flow time is set to 20 seconds and the closing of the distal and opening of the proximal valves takes 3 seconds, the controller may be configured to retain plunger 310 at the upper squeezing position for an additional 17 seconds, prior to commencing delivery by lowering plunger 310 to the lower squeezing position after the valves are switched back to delivery position. The wait period ensures full engagement of infusion tube 350 with plunger 310 prior to infusion fluid delivery and thus guarantees that an exact and constant amount of infusion fluid is delivered to the patient. In addition, by preventing continuous ascending/relaxing of infusion tube 350 during delivery (which may occur if full engagement between infusion tube 350 and plunger 310 is not achieved), liquid may be sucked from the patient into infusion tube 350. This may in turn result in blood entering the catheter and the tube, and cause occlusions in the infusion tube. In addition, the blood in the tube is also often found visually unpleasant to the patient and his/her surroundings. Defining a wait period may be of particular importance for low flow rate delivery in which case infusion tube 350 is squeezed by plunger 310 (in its lower squeezing position) for a prolonged period of time (e.g. 1-3 hours depending on the plunger length, tube ID and flow rate). The intake of the infusion fluid has a short duration (a few seconds) and, without the wait, will not be sufficient to recover the tube to the original upper position of the plunger, hence, will reduce the intake volume.
According to some embodiments, the controller may be further configured to trigger an elevating of plunger 310 to a position above the upper squeezing position (but still somewhat squeezed), while proximal valve 320 is open, and distal valve 325 closed, such that lowering of plunger 310 to the upper squeezing position causes a small bolus of infusion fluid to flow into the reservoir. Such initial backflow may be particularly advantageous when the infusion source is a syringe, in that it enables reducing the residual vacuum created within the syringe.
Reference is now made to
Steps 410 to 450 are steps associated with intake of infusion fluid from a reservoir (also referred to herein as infusion source).
In step 410 an infusion tube is positioned within an infusion pump comprising a plunger, a proximal valve located proximally to the plunger, and a distal valve located distally to the plunger.
In step 420 an opening of the proximal valve and a closing of the distal valve is triggered, followed by a positioning of the plunger in an upper squeezing position at which the infusion tube is mildly squeezed (step 440), yet without having opposite sides of the inner surface of its squeezed section contacting one another, thereby causing intake of fluid from a reservoir.
Optionally, prior to positioning the plunger in its upper squeezing position, the method may include a step 430 in which the plunger is, for most of the wait time, elevated to a position above the upper squeezing position, (while the proximal valve is open, and the distal valve closed). This step may be particularly advantageous when the reservoir is a syringe in that it allows a small bolus of infusion fluid to flow into the syringe, thus reducing the residual vacuum created therein during the intake.
Optionally, after intake of infusion fluid from the reservoir is completed, the method may further include a step 450 at which the plunger “waits” at the upper squeezing position for the longest time the flow continuity and the flow rate permits, so as to ensure full engagement of the infusion tube with the plunger. According to some embodiments, the length of the wait period may depend on the length of the intake and may, for example, range between 2 seconds and 18 seconds when the required flow continuity is to have a maximum delivery every 20 seconds. If the flow continuity is defined by 10 minutes of maximum no flow time, the wait can last 10 minutes minus a few seconds. The choice of wait is the longest possible under the specific flow continuity and flow rate requirements.
Steps 460 to 470 are steps associated with delivery of the infusion fluid to a patient.
In step 460 the plunger is held in the upper squeezing position while closing of the proximal valve and opening of the distal valve is triggered. Subsequently, in step 470, a descending of the plunger from the upper squeezing position to a lower squeezing position is triggered, thereby causing the infusion tube to be further squeezed yet still without having opposite sides of the inner surface of its squeezed section contacting one another. As a result, delivery of an essentially constant volume of the infusion fluid to a subject is facilitated, regardless of a potential degradation of the infusion tube.
In order to evaluate the flow rate stability of the hereindisclosed infusion pump a comparative study was set up. The study evaluated the flow rate over time of an infusion fluid delivered by the hereindisclosed infusion pump (Avoset) as compared to that obtained using a known infusion pump including a compensation algorithm configured to mathematically compensate for changes in flow rate caused by tube degradation.
As seen from
This result clearly emphasizes the unexpected and convincing advantage of the hereindisclosed infusion pump, which is capable of ensuring a constant delivery of infusion fluid for 40 hours and more.
The terminology used herein is for the purpose of describing particular embodiments only and is not intended to be limiting. As used herein, the singular forms “a”, “an” and “the” are intended to include the plural forms as well, unless the context clearly indicates otherwise. It will be further understood that the terms “comprises” or “comprising,” when used in this specification, specify the presence of stated features, integers, steps, operations, elements, or components, but do not preclude or rule out the presence or addition of one or more other features, integers, steps, operations, elements, components, or groups thereof.
Unless specifically stated otherwise, as apparent from the following discussions, it is appreciated that throughout the specification discussions utilizing terms such as “processing”, “computing”, “calculating”, “determining”, “estimating”, or the like, refer to the action and/or processes of a computer or computing system, or similar electronic computing device, that manipulate and/or transform data represented as physical, such as electronic, quantities within the computing system's registers and/or memories into other data similarly represented as physical quantities within the computing system's memories, registers or other such information storage, transmission or display devices.
Embodiments of the present invention may include apparatuses for performing the operations herein. This apparatus may be specially constructed for the desired purposes, or it may comprise a general purpose computer selectively activated or reconfigured by a computer program stored in the computer. Such a computer program may be stored in a computer readable storage medium, such as, but not limited to, any type of read-only memories (ROMs), random access memories (RAMs), electrically programmable read-only memories (EPROMs), electrically erasable and programmable read only memories (EEPROMs), or any other type of media suitable for storing electronic instructions, and capable of being coupled to a computer system bus.
The processes and displays presented herein are not inherently related to any particular computer or other apparatus. Various general purpose systems may be used with programs in accordance with the teachings herein, or it may prove convenient to construct a more specialized apparatus to perform the desired method. The desired structure for a variety of these systems will appear from the description below. In addition, embodiments of the present invention are not described with reference to any particular programming language. It will be appreciated that a variety of programming languages may be used to implement the teachings of the inventions as described herein.
The invention may be described in the general context of computer-executable instructions, such as program modules, being executed by a computer. Generally, program modules include routines, programs, objects, components, data structures, and so forth, which perform particular tasks or implement particular abstract data types. The invention may also be practiced in distributed computing environments where tasks are performed by remote processing devices that are linked through a communications network. In a distributed computing environment, program modules may be located in both local and remote computer storage media including memory storage devices.
While a number of exemplary aspects and embodiments have been discussed above, those of skill in the art will recognize certain modifications, additions and sub-combinations thereof. It is therefore intended that the following appended claims and claims hereafter introduced be interpreted to include all such modifications, additions and sub-combinations as are within their true spirit and scope.
This application is a National Phase of PCT Patent Application No. PCT/IL2018/050409 having International filing date of Apr. 9, 2018, which claims the benefit of priority of U.S. Provisional Application No. 62/629,038 filed on Feb. 11, 2018. The contents of the above applications are all incorporated by reference as if fully set forth herein in their entirety.
Filing Document | Filing Date | Country | Kind |
---|---|---|---|
PCT/IL2018/050409 | 4/9/2018 | WO |
Publishing Document | Publishing Date | Country | Kind |
---|---|---|---|
WO2019/155453 | 8/15/2019 | WO | A |
Number | Name | Date | Kind |
---|---|---|---|
3379950 | Friedline | Apr 1968 | A |
3778195 | Bamberg | Dec 1973 | A |
4236880 | Archibald | Dec 1980 | A |
4314567 | Cannon | Feb 1982 | A |
4322668 | Trussler et al. | Mar 1982 | A |
4391600 | Archibald | Jul 1983 | A |
4650469 | Berg et al. | Mar 1987 | A |
5018945 | D'Silva | May 1991 | A |
5049047 | Polaschegg et al. | Sep 1991 | A |
5096385 | Georgi et al. | Mar 1992 | A |
5116203 | Natwick | May 1992 | A |
5340951 | Hungerbuhler et al. | Aug 1994 | A |
5437642 | Thill et al. | Aug 1995 | A |
5807075 | Jacobsen et al. | Sep 1998 | A |
5807322 | Lindsey et al. | Sep 1998 | A |
5843035 | Bowman et al. | Dec 1998 | A |
5924852 | Moubayed et al. | Jul 1999 | A |
5954485 | Johnson et al. | Sep 1999 | A |
6312227 | Davis | Nov 2001 | B1 |
6494864 | Kerwin et al. | Dec 2002 | B1 |
6523414 | Malmstrom et al. | Feb 2003 | B1 |
6531708 | Malmstrom et al. | Mar 2003 | B1 |
6554806 | Butterfield et al. | Apr 2003 | B2 |
6659976 | Beck et al. | Dec 2003 | B2 |
6679862 | Diaz et al. | Jan 2004 | B2 |
6702779 | Connelly et al. | Mar 2004 | B2 |
6750468 | Malmstrom et al. | Jun 2004 | B2 |
6852094 | Beck et al. | Feb 2005 | B2 |
6889556 | Steger | May 2005 | B2 |
6907788 | Malmstrom et al. | Jun 2005 | B2 |
6908452 | Diaz et al. | Jun 2005 | B2 |
6979311 | Miles et al. | Dec 2005 | B2 |
7048715 | Diaz et al. | May 2006 | B2 |
7059840 | Corwin et al. | Jun 2006 | B2 |
7070575 | Beck et al. | Jul 2006 | B2 |
7092796 | Vanderveen | Aug 2006 | B2 |
7121143 | Malmstrom et al. | Oct 2006 | B2 |
7163381 | Barak | Jan 2007 | B1 |
7356382 | Vanderveen | Apr 2008 | B2 |
7384408 | Barak | Jun 2008 | B2 |
7497842 | Diaz et al. | Mar 2009 | B2 |
7695448 | Cassidy et al. | Apr 2010 | B2 |
7726174 | Riley et al. | Jun 2010 | B2 |
7758551 | Wiesner et al. | Jul 2010 | B2 |
7819838 | Ziegler et al. | Oct 2010 | B2 |
7875004 | Yodfat et al. | Jan 2011 | B2 |
7881883 | Remde | Feb 2011 | B2 |
7892199 | Mhatre et al. | Feb 2011 | B2 |
7896197 | Furey et al. | Mar 2011 | B2 |
7921718 | Malmstrom et al. | Apr 2011 | B2 |
7922700 | Evans et al. | Apr 2011 | B2 |
7967773 | Amborn et al. | Jun 2011 | B2 |
7981082 | Wang et al. | Jul 2011 | B2 |
8025654 | Barak | Sep 2011 | B2 |
8034020 | Dewey | Oct 2011 | B2 |
8048022 | Moy et al. | Nov 2011 | B2 |
8081069 | Haueter et al. | Dec 2011 | B2 |
8105269 | Zhou | Jan 2012 | B2 |
8142400 | Rotem et al. | Mar 2012 | B2 |
8152780 | Evans et al. | Apr 2012 | B2 |
8167832 | Bowman et al. | May 2012 | B2 |
8182461 | Pope et al. | May 2012 | B2 |
8225639 | Riley et al. | Jul 2012 | B2 |
8232484 | Hauck | Jul 2012 | B2 |
8286505 | Wade | Oct 2012 | B2 |
8287495 | Michaud et al. | Oct 2012 | B2 |
8298184 | Diperna et al. | Oct 2012 | B2 |
8328786 | Strickler et al. | Dec 2012 | B2 |
8343111 | Beck et al. | Jan 2013 | B2 |
8361021 | Wang et al. | Jan 2013 | B2 |
8378837 | Wang et al. | Feb 2013 | B2 |
8394051 | Geipel | Mar 2013 | B2 |
8419676 | Evans et al. | Apr 2013 | B2 |
8448523 | Richter | May 2013 | B2 |
8486005 | Yodfat et al. | Jul 2013 | B2 |
8486020 | Hills et al. | Jul 2013 | B2 |
8496613 | Zhou | Jul 2013 | B2 |
8539672 | Eggers et al. | Sep 2013 | B2 |
8567235 | Bojan et al. | Oct 2013 | B2 |
8641671 | Michaud et al. | Feb 2014 | B2 |
8657778 | Ziegler et al. | Feb 2014 | B2 |
8690014 | Haueter et al. | Apr 2014 | B2 |
8690860 | Abal | Apr 2014 | B2 |
8733178 | Bivans et al. | May 2014 | B2 |
8752436 | Beck et al. | Jun 2014 | B2 |
8758323 | Michaud et al. | Jun 2014 | B2 |
8771227 | Connelly et al. | Jul 2014 | B2 |
8795225 | Lewis et al. | Aug 2014 | B2 |
8808230 | Rotstein | Aug 2014 | B2 |
8821432 | Unverdorben | Sep 2014 | B2 |
8852141 | Mhatre et al. | Oct 2014 | B2 |
8859972 | Cummings et al. | Oct 2014 | B2 |
8876787 | Beck et al. | Nov 2014 | B2 |
8900213 | Pope et al. | Dec 2014 | B2 |
8926561 | Verhoef et al. | Jan 2015 | B2 |
8943894 | Geipel | Feb 2015 | B2 |
8945064 | Gravesen et al. | Feb 2015 | B2 |
8961453 | Bowman et al. | Feb 2015 | B2 |
8974415 | Robert et al. | Mar 2015 | B2 |
8986253 | Diperna et al. | Mar 2015 | B2 |
9004886 | Beck et al. | Apr 2015 | B2 |
9005153 | Kopperschmidt et al. | Apr 2015 | B2 |
9017296 | Beck et al. | Apr 2015 | B2 |
9033923 | Hartman et al. | May 2015 | B2 |
9101712 | Denis et al. | Aug 2015 | B2 |
9109966 | Duits | Aug 2015 | B2 |
9132230 | Blomquist | Sep 2015 | B2 |
9162023 | Barnes et al. | Oct 2015 | B2 |
9173998 | Rosinko et al. | Nov 2015 | B2 |
9211377 | Diperna et al. | Dec 2015 | B2 |
9227008 | Magnenat et al. | Jan 2016 | B2 |
9234850 | Hammond et al. | Jan 2016 | B2 |
9248230 | Geipel et al. | Feb 2016 | B2 |
9272087 | Halbert et al. | Mar 2016 | B2 |
9285324 | Leuenberger Jockel | Mar 2016 | B2 |
9308323 | Adams | Apr 2016 | B2 |
9375531 | Lee et al. | Jun 2016 | B1 |
9408968 | Browne et al. | Aug 2016 | B2 |
9415158 | Miller et al. | Aug 2016 | B2 |
9427521 | Pope et al. | Aug 2016 | B2 |
9468713 | Hoenninger, III et al. | Oct 2016 | B2 |
9474854 | Mhatre et al. | Oct 2016 | B2 |
9480793 | Mhatre et al. | Nov 2016 | B2 |
9480794 | Keith et al. | Nov 2016 | B2 |
9545478 | Abal | Jan 2017 | B2 |
9561323 | Plahey et al. | Feb 2017 | B2 |
9603998 | Geipel et al. | Mar 2017 | B2 |
9610404 | Rotstein | Apr 2017 | B2 |
9642777 | Lewis et al. | May 2017 | B2 |
9662437 | Moosai | May 2017 | B2 |
9675756 | Kamen et al. | Jun 2017 | B2 |
9677555 | Kamen et al. | Jun 2017 | B2 |
9682192 | Marsh et al. | Jun 2017 | B2 |
9683562 | Davis et al. | Jun 2017 | B2 |
9717849 | Mhatre et al. | Aug 2017 | B2 |
9757517 | Eberhard | Sep 2017 | B2 |
9770552 | Hartman et al. | Sep 2017 | B2 |
9775947 | Keith et al. | Oct 2017 | B2 |
9789251 | Robert et al. | Oct 2017 | B2 |
9839744 | Muto et al. | Dec 2017 | B2 |
9879668 | Yavorsky et al. | Jan 2018 | B2 |
9901676 | Mijers et al. | Feb 2018 | B2 |
9932977 | Bresina et al. | Apr 2018 | B2 |
9937290 | Connelly et al. | Apr 2018 | B2 |
9937291 | Eberhard | Apr 2018 | B2 |
9958344 | Burkhard | May 2018 | B2 |
9962486 | Rosinko et al. | May 2018 | B2 |
9987424 | Kim | Jun 2018 | B2 |
9995642 | Shimoyama et al. | Jun 2018 | B2 |
10004847 | Wander et al. | Jun 2018 | B2 |
10006453 | Girard et al. | Jun 2018 | B2 |
10022494 | Shimizu | Jul 2018 | B2 |
10022495 | Halbert et al. | Jul 2018 | B2 |
10022496 | Geipel et al. | Jul 2018 | B2 |
10046112 | Oruklu et al. | Aug 2018 | B2 |
10080836 | Juretich et al. | Sep 2018 | B2 |
10092697 | Nessel et al. | Oct 2018 | B2 |
10112009 | Dudar et al. | Oct 2018 | B2 |
10151646 | Heo et al. | Dec 2018 | B2 |
10539453 | Hauck | Jan 2020 | B2 |
20030141468 | Malmstrom et al. | Jul 2003 | A1 |
20050107923 | Vanderveen | May 2005 | A1 |
20060173412 | Susi | Aug 2006 | A1 |
20060189926 | Hall et al. | Aug 2006 | A1 |
20060206054 | Shekalim | Sep 2006 | A1 |
20060229531 | Goldberger | Oct 2006 | A1 |
20070123781 | Callahan et al. | May 2007 | A1 |
20070179435 | Braig et al. | Aug 2007 | A1 |
20080283296 | Zamora et al. | Nov 2008 | A1 |
20090221964 | Rotem et al. | Sep 2009 | A1 |
20090240201 | Rotem et al. | Sep 2009 | A1 |
20090293588 | Riley et al. | Dec 2009 | A1 |
20100106082 | Zhou | Apr 2010 | A1 |
20100114001 | O'Mahony | May 2010 | A1 |
20100212407 | Stringham et al. | Aug 2010 | A1 |
20100280446 | Kalpin | Nov 2010 | A1 |
20110087165 | Amborn et al. | Apr 2011 | A1 |
20110152772 | Rotem et al. | Jun 2011 | A1 |
20110190606 | Gable et al. | Aug 2011 | A1 |
20120205312 | Hogard | Aug 2012 | A1 |
20120238949 | Kalpin | Sep 2012 | A1 |
20120330574 | Ruiter et al. | Dec 2012 | A1 |
20130035659 | Hungerford et al. | Feb 2013 | A1 |
20130071271 | Rosen et al. | Mar 2013 | A1 |
20130226129 | Unverdorben | Aug 2013 | A1 |
20130336814 | Kamen et al. | Dec 2013 | A1 |
20140066850 | Robert et al. | Mar 2014 | A1 |
20140119954 | Schweitzer et al. | May 2014 | A1 |
20140121639 | Lowery et al. | May 2014 | A1 |
20140228755 | Darrah et al. | Aug 2014 | A1 |
20150005732 | Halbert et al. | Jan 2015 | A1 |
20150238689 | Shimizu | Aug 2015 | A1 |
20150292500 | Girard et al. | Oct 2015 | A1 |
20150367120 | Kusters et al. | Dec 2015 | A1 |
20180140770 | Hetchler et al. | May 2018 | A1 |
20180200456 | Eitan et al. | Jul 2018 | A1 |
20180318505 | Eitan et al. | Nov 2018 | A1 |
20200282138 | Eitan et al. | Sep 2020 | A1 |
Number | Date | Country |
---|---|---|
0182502 | May 1986 | EP |
1381843 | Mar 2009 | EP |
2040056 | Sep 2010 | EP |
1381889 | Mar 2016 | EP |
2570826 | Aug 2016 | EP |
3705148 | Sep 2020 | EP |
2553151 | Apr 1985 | FR |
2150644 | Jul 1985 | GB |
103727021 | Apr 2014 | IN |
02068018 | Sep 2002 | WO |
2012126744 | Sep 2012 | WO |
2019155453 | Aug 2019 | WO |
2020178824 | Sep 2020 | WO |
Entry |
---|
Extended European Search Report for European Application No. 21194042.4, dated Feb. 17, 2022., 7 pp. |
An Office Action dated Sep. 30, 2019, which issued during the prosecution of U.S. Appl. No. 15/740,365. |
European Search Report dated Jun. 21, 2019 which issued during the prosecution of European Application No. 16817348.2. |
An International Search Report and a Written Opinion both dated Aug. 5, 2018, which issued during the prosecution of Applicant's PCT/IL2018/050409. |
U.S. Appl. No. 62/813,292, filed Mar. 4, 2019. |
European Search Report dated Jun. 4, 2020, which issued during the prosecution of Applicant's European App No. 20160966.6. |
An Office Action dated Jun. 22, 2020, which issued during the prosecution of U.S. Appl. No. 15/740,365. |
An International Search Report and a Written Opinion both dated Jun. 9, 2020, which issued during the prosecution of Applicant's PCT/IL2020/050246. |
An International Search Report and a Written Opinion both dated May 15, 2020, which issued during the prosecution of Applicant's PCT/IL2020/050249. |
U.S. Appl. No. 62/629,038, filed Feb. 11, 2018. |
European Search Report dated May 12, 2021 which issued during the prosecution of Applicant's European App No. 20212979.7. |
European Search Report dated Oct. 8, 2021 which issued during the prosecution of Applicant's European App No. 18905766.4., 8pp. |
Notice of Allowance dated Aug. 4, 2021, which issued during the prosecution of U.S. Appl. No. 16/808,652, 79pp. |
Number | Date | Country | |
---|---|---|---|
20210001036 A1 | Jan 2021 | US |
Number | Date | Country | |
---|---|---|---|
62629038 | Feb 2018 | US |